Enanta Pharmaceuticals Inc (ENTA)

[vinmantoo]

The Paxlovid standard risk population trial did not meet its endpoint with statistical significance.

Yes, but that won't be the target population for EDP-235 in phase 3. EDP-235 will be going the high risk population and the elderly, you know, the population where Paxlovid is racking in $20 billion in 2022 alone. By the way, Paxlovid's failure in the standard risk population represents an unmet need.